Pravachol Low Drug Interaction Profile Deemed Favorable During OTC Review
This article was originally published in The Tan Sheet
Executive Summary
The drug interaction profile of Bristol-Myers Squibb's Pravachol may make the cholesterol-lowering agent a more attractive OTC switch candidate than Merck's Mevacor, FDA advisory committee members suggested.
You may also be interested in...
NDAC/Endocrinologic Drug Joint Panel Meeting Likely To Focus On Statins
A two-day joint meeting of the Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees is scheduled for Jan. 13-14, 2005
NDAC/Endocrinologic Drug Joint Panel Meeting Likely To Focus On Statins
A two-day joint meeting of the Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees is scheduled for Jan. 13-14, 2005
NDAC/Endocrinologic Drug Joint Panel Meeting Likely To Focus On Statins
A two-day joint meeting of the Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees is scheduled for Jan. 13-14, 2005